A rapid and sensitive HPLC-MS method for the detection of plasma and cellular rifampicin

被引:34
作者
Hartkoorn, Ruben C.
Khoo, Saye
Back, David J.
Tjia, John F.
Waitt, Catriona J.
Chaponda, Masautso
Davies, Geraint
Ardrey, Alison
Ashleigh, Samantha
Ward, Stephen A.
机构
[1] Univ Liverpool, Dept Pharm & Therapeut, Liverpool L69 3GF, Merseyside, England
[2] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2007年 / 857卷 / 01期
关键词
rifampicin; HPLC-MS; plasma; cellular;
D O I
10.1016/j.jchromb.2007.07.005
中图分类号
Q5 [生物化学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Rifampicin is active against both intracellular and extracellular Mycobacterium tuberculosis. The ability to measure rifampicin drug concentrations in both plasma and in cells may be useful in evaluating the suitability of dosage regimens for populations and individuals. Here a novel simple. precise and accurate method for the quantification of rifampicin in both cells and plasma is reported. Sample proteins were precipitated with acetonitrile containing the internal standard and then diluted with water. Aliquots of supernatant were then injected into the HPLC-MS system for chromatographic separation and detection. Rifampicin calibration curves encompassed concentrations from 100 to 12,800 ng/mL. Intraand inter-assay precision and accuracy were determined using low, medium and high concentration quality control samples and was found to be within 10% in all cases. Rifampicin concentrations were found to be unaffected by freeze-thaw cycles, but were significantly affected by heat-inactivation (58 degrees C 40 min). This assay was successfully utilised to determine the pharmacokinetic profile of rifampicin in plasma and peripheral blood mononuclear cells (PBMC) in 8 tuberculosis patients receiving rifampicin over an 8 h period. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:76 / 82
页数:7
相关论文
共 20 条
[1]
KINETIC STUDIES ON RIFAMPICIN .1. SERUM CONCENTRATION ANALYSIS IN SUBJECTS TREATED WITH DIFFERENT ORAL DOSES OVER A PERIOD OF 2 WEEKS [J].
ACOCELLA, G ;
BARONI, GC ;
MARCHETTI, M ;
PAGANI, V ;
NICOLIS, FB .
CHEMOTHERAPY, 1971, 16 (06) :356-+
[2]
Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individuals [J].
Almond, LM ;
Edirisinghe, D ;
Dalton, M ;
Bonington, A ;
Back, DJ ;
Khoo, SH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (02) :132-142
[3]
[Anonymous], 2001, BIOAN METH VAL GUID
[4]
High-performance liquid-chromatographic determination of rifampicin in plasma and tissues [J].
Calleja, I ;
Blanco-Príeto, MJ ;
Ruz, N ;
Renedo, MJ ;
Dios-Viéitez, MC .
JOURNAL OF CHROMATOGRAPHY A, 2004, 1031 (1-2) :289-294
[5]
Validation of a RP-LC method for the simultaneous determination of isoniazid, pyrazinamide and rifampicin in a pharmaceutical formulation [J].
Calleri, E ;
De Lorenzi, E ;
Furlanetto, S ;
Massolini, G ;
Caccialanza, G .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 29 (06) :1089-1096
[6]
DOLLERY C, 1998, RIFAMPIN THERAPEUTIC, pR32
[7]
Ford J, 2004, ANTIVIR THER, V9, P77
[8]
Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients [J].
Ford, J ;
Boffito, M ;
Wildfire, A ;
Hill, A ;
Back, D ;
Khoo, S ;
Nelson, M ;
Moyle, G ;
Gazzard, B ;
Pozniak, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) :2388-2393
[9]
FORSGREN A, 1985, SCAND J INFECT DIS, P16
[10]
LOW-LEVELS OF DEOXYNUCLEOTIDES IN PERIPHERAL-BLOOD LYMPHOCYTES - A STRATEGY TO INHIBIT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REPLICATION [J].
GAO, WY ;
CARA, A ;
GALLO, RC ;
LORI, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (19) :8925-8928